{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:25:20Z","timestamp":1789575920496,"version":"build-2803163510"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Long COVID is increasingly recognized as a biologically heterogeneous, multisystem condition with wide variability in symptom expression and treatment response. Although symptom-based phenotyping has advanced descriptive and epidemiologic understanding, similarity in clinical presentation does not necessarily imply shared upstream pathophysiology. Therapeutic cohorts defined solely by symptom clusters may therefore combine biologically distinct mechanisms, potentially diluting treatment effects and complicating interpretation of interventional trials. This manuscript proposes a complementary, mechanism-anchored framework centered on recurrent and biologically measurable domains: autonomic dysfunction, mitochondrial and bioenergetic impairment, endothelial and microvascular dysfunction, gut dysbiosis and barrier disruption, mast cell\u2013mediated signaling, and neuroendocrine dysregulation. These primary domains are conceptualized as physiologically coherent systems capable of generating multisystem symptom patterns in biologically enriched subsets. Secondary amplifying processes, including persistent immune activation, viral antigen persistence without established replication, autoantibody formation, neuroinflammation, and sleep-related destabilization, are positioned as network-coupling processes that may sustain or amplify dysregulation across domains. Within a network-based framework, Long COVID is conceptualized as a network disorder in which interacting regulatory nodes are hypothesized to generate self-reinforcing feedback loops that maintain symptom persistence even after resolution of acute infection. The model accommodates heterogeneity across mechanisms and alternative explanatory hypotheses. It provides an operational structure for organizing mechanistic heterogeneity and generating testable predictions. A prototype, unvalidated screening instrument is included to illustrate a potential pathway toward mechanism-informed stratification and prospective trial enrichment. Future research should evaluate whether biologically enriched cohorts demonstrate differential therapeutic responsiveness compared with symptom-defined populations. Prospective validation using standardized physiological metrics will be essential to determine whether mechanism-guided stratification improves translational precision and clarifies actionable pathophysiology in Long COVID.<\/jats:p>","DOI":"10.3389\/fmed.2026.1841690","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:47:56Z","timestamp":1780030076000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Long COVID as a network disorder: a mechanism-anchored framework for biological stratification and therapeutic targeting"],"prefix":"10.3389","volume":"13","author":[{"given":"Robert","family":"Groysman","sequence":"first","affiliation":[{"name":"Independent Researcher","place":["Plano, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome","volume":"27","author":"Nalbandian","year":"2021","journal-title":"Nat Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"16144","DOI":"10.1038\/s41598-021-95565-8","article-title":"More than 50 long-term effects of COVID-19: a systematic review and meta-analysis","volume":"11","author":"Lopez-Leon","year":"2021","journal-title":"Sci Rep"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41591-021-01292-y","article-title":"Attributes and predictors of long COVID","volume":"27","author":"Sudre","year":"2021","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1001\/jama.2024.24184","article-title":"2024 update of the RECOVER-adult long COVID research index","volume":"333","author":"Geng","year":"2025","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0140-6736(24)01136-X","article-title":"Long COVID: a clinical update","volume":"404","author":"Greenhalgh","year":"2024","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1001\/jama.2022.18931","article-title":"Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021","volume":"328","year":"2022","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"100122","DOI":"10.1016\/j.lanepe.2021.100122","article-title":"Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study","volume":"6","author":"Augustin","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1016\/j.cell.2024.07.054","article-title":"Mechanisms of long COVID and the path toward therapeutics","volume":"187","author":"Peluso","year":"2024","journal-title":"Cell"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41591-022-02116-3","article-title":"Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes","volume":"29","author":"Zhang","year":"2023","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e2426874122","DOI":"10.1073\/pnas.2426874122","article-title":"Patient-reported treatment outcomes in ME\/CFS and long COVID","volume":"122","author":"Eckey","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.7861\/clinmed.2020-0896","article-title":"Autonomic dysfunction in long COVID","volume":"21","author":"Dani","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41467-023-44432-3","article-title":"Long-COVID postural tachycardia syndrome","volume":"18","author":"Raj","year":"2021","journal-title":"Heart Rhythm"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41467-023-44432-3","article-title":"Muscle abnormalities worsen after post-exertional malaise in long COVID","volume":"15","author":"Appelman","year":"2024","journal-title":"Nat Commun"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/gutjnl-2021-325989","article-title":"Gut microbiota dynamics in post-acute COVID-19 syndrome","volume":"71","author":"Liu","year":"2022","journal-title":"Gut"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/all.15188","article-title":"Mast cell activation is associated with post-acute COVID-19 syndrome","volume":"77","author":"Wechsler","year":"2021","journal-title":"Allergy"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ijid.2021.09.043","article-title":"Mast cell activation symptoms are prevalent in long-COVID","volume":"112","author":"Weinstock","year":"2021","journal-title":"Int J Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1202696","DOI":"10.3389\/fcvm.2023.1202696","article-title":"Antihistamines improve cardiovascular manifestations and other symptoms of long COVID attributed to mast cell activation","volume":"10","author":"Salvucci","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e13407","DOI":"10.1111\/sji.13407","article-title":"No signs of mast cell involvement in long-COVID: a case\u2013control study","volume":"100","author":"Lenning","year":"2024","journal-title":"Scand J Immunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"bqab203","DOI":"10.1210\/endocr\/bqab203","article-title":"Impact of COVID-19 on the endocrine system: a mini-review","volume":"163","author":"Clarke","year":"2021","journal-title":"Endocrinology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.3390\/cells10113263","article-title":"Treatable traits in chronic respiratory disease: a comprehensive review","volume":"10","author":"Lee","year":"2021","journal-title":"Cells"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"104784","DOI":"10.1016\/j.ebiom.2023.104784","article-title":"Long-COVID cognitive impairments and reproductive hormone deficits in men may stem from GnRH neuronal death","volume":"96","author":"Sauve","year":"2023","journal-title":"EBioMedicine"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/13102818.2023.2170829","article-title":"Thyroid dysfunction as a long-term post-COVID-19 complication in mild-to-moderate COVID-19","volume":"37","author":"Yanachkova","year":"2023","journal-title":"Biotechnol Biotechnol Equip"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.eprac.2021.06.016","article-title":"Long COVID in patients with mild to moderate disease: do thyroid function and autoimmunity play a role?","volume":"27","author":"Lui","year":"2021","journal-title":"Endocr Pract"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41586-023-06651-y","article-title":"Distinguishing features of long COVID identified through immune profiling","volume":"623","author":"Klein","year":"2023","journal-title":"Nature"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: major findings, mechanisms and recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S1473-3099(24)00171-3","article-title":"The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China","volume":"24","author":"Zuo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41586-022-05542-y","article-title":"SARS-CoV-2 infection and persistence in the human body and brain at autopsy","volume":"612","author":"Stein","year":"2022","journal-title":"Nature"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/j.neuroscience.2024.10.021","article-title":"Autoantibodies in long COVID: a systematic review","volume":"26","author":"Wilhelm","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jamapsychiatry.2023.0664","article-title":"Does microglial activation lead to cognitive changes after COVID-19 infection?","volume":"80","author":"Gerhard","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.cell.2022.06.008","article-title":"Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation","volume":"185","author":"Fern\u00e1ndez-Casta\u00f1eda","year":"2022","journal-title":"Cell"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e200244","DOI":"10.1212\/NXI.0000000000200244","article-title":"Small fiber neuropathy associated with SARS-CoV-2 infection","volume":"11","author":"McAlpine","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrg2918","article-title":"Network medicine: a network-based approach to human disease","volume":"12","author":"Barab\u00e1si","year":"2011","journal-title":"Nat Rev Genet"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1001\/jamainternmed.2024.2007","article-title":"Nirmatrelvir-ritonavir and symptoms in adults with post-acute sequelae of SARS-CoV-2 infection: the STOP-PASC randomized clinical trial","volume":"184","author":"Geng","year":"2024","journal-title":"JAMA Intern Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/all.15188","article-title":"Nirmatrelvir\u2013ritonavir versus placebo\u2013ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial","volume":"25","author":"Sawano","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e0272472","DOI":"10.1371\/journal.pone.0272472","article-title":"STIMULATE-ICP: a pragmatic, multicentre, cluster randomised trial with nested adaptive platform drug trial in long COVID","volume":"18","author":"Forshaw","year":"2023","journal-title":"PLoS One"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1802058","DOI":"10.1183\/13993003.02058-2018","article-title":"Treatable traits in chronic respiratory disease","volume":"53","author":"McDonald","year":"2019","journal-title":"Eur Respir J"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jaip.2023.01.011","article-title":"Treatable traits in airway disease: from theory to practice","volume":"11","author":"Agusti","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/bmjebm-2022-111952","article-title":"Adapt or die: how the pandemic made the shift from EBM to EBM+ more urgent","volume":"27","author":"Greenhalgh","year":"2022","journal-title":"BMJ Evid Based Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1258\/jrsm.2010.100146","article-title":"Evidence-based mechanistic reasoning","volume":"103","author":"Howick","year":"2010","journal-title":"J R Soc Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/jep.13438","article-title":"The use of mechanistic reasoning in assessing coronavirus interventions","volume":"27","author":"Aronson","year":"2021","journal-title":"J Eval Clin Pract"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"686240","DOI":"10.3389\/fimmu.2021.686240","article-title":"Plasma markers of disrupted gut permeability in severe COVID-19 patients","volume":"12","author":"Giron","year":"2021","journal-title":"Front Immunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1118625","DOI":"10.3389\/fcvm.2023.1118625","article-title":"Gut permeability-related endotoxemia and cardiovascular disease: a new clinical challenge","volume":"10","author":"Violi","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.33963\/KP.a2023.0115","article-title":"Gut dysbiosis-derived low-grade endotoxemia: a common basis for liver and cardiovascular disease","volume":"81","author":"Violi","year":"2023","journal-title":"Kardiol Pol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/cdd.2012.81","article-title":"The pathways of mitophagy for quality control and clearance of mitochondria","volume":"20","author":"Ashrafi","year":"2013","journal-title":"Cell Death Differ"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s42234-025-00167-8","article-title":"Long COVID - a critical disruption of cholinergic neurotransmission?","volume":"11","author":"Leitzke","year":"2025","journal-title":"Bioelectron Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12933-021-01359-7","article-title":"Persistent clotting protein pathology in long COVID\/post-acute sequelae of COVID-19","volume":"20","author":"Pretorius","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1016\/j.cell.2023.09.013","article-title":"Serotonin reduction in post-acute sequelae of viral infection","volume":"186","author":"Wong","year":"2023","journal-title":"Cell"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1152\/physrev.00018.2018","article-title":"The microbiota\u2013gut\u2013brain axis","volume":"99","author":"Cryan","year":"2019","journal-title":"Physiol Rev"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.cell.2016.10.027","article-title":"The central nervous system and the gut microbiome","volume":"167","author":"Sharon","year":"2016","journal-title":"Cell"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.neuroscience.2024.10.021","article-title":"The tryptophan catabolite or kynurenine pathway in long COVID disease: a systematic review and meta-analysis","volume":"563","author":"Almulla","year":"2024","journal-title":"Neuroscience"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"BSR20230595","DOI":"10.1042\/BSR20230595","article-title":"The kynurenine pathway of tryptophan metabolism: a neglected therapeutic target of COVID-19 pathophysiology and immunotherapy","volume":"43","author":"Badawy","year":"2023","journal-title":"Biosci Rep"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1005937","DOI":"10.3389\/fimmu.2022.1005937","article-title":"Interleukin-6 and indoleamine-2,3-dioxygenase as potential immunometabolic adjuvants for immunotherapies","volume":"13","author":"Pagni","year":"2022","journal-title":"Front Immunol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s42234-025-00167-8","article-title":"Long COVID \u2013 a critical disruption of cholinergic neurotransmission?","volume":"11","author":"Leitzke","year":"2025","journal-title":"Bioelectron Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3390\/pharmaceutics14050971","article-title":"A single-cell network-based drug repositioning strategy for post-COVID-19 pulmonary fibrosis","volume":"14","author":"Li","year":"2022","journal-title":"Pharmaceutics"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41591-022-01810-6","article-title":"Unexplained post-acute infection syndromes","volume":"28","author":"Choutka","year":"2022","journal-title":"Nat Med"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/S0140-6736(20)31189-2","article-title":"Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in new York City: a prospective cohort study","volume":"395","author":"Cummings","year":"2020","journal-title":"Lancet"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1841690\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:48:02Z","timestamp":1780030082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1841690\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":56,"alternative-id":["10.3389\/fmed.2026.1841690"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1841690","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1841690"}}